Biohaven Pharmaceutical Holding Stock Buy Hold or Sell Recommendation
| BHVN Stock | USD 29.15 0.93 3.30% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Biohaven Pharmaceutical Holding is 'Strong Sell'. The recommendation algorithm takes into account all of Biohaven Pharmaceutical's available fundamental, technical, and predictive indicators you will find on this site.
Check out Biohaven Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Biohaven and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Biohaven |
Execute Biohaven Pharmaceutical Buy or Sell Advice
The Biohaven recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Biohaven Pharmaceutical Holding. Macroaxis does not own or have any residual interests in Biohaven Pharmaceutical Holding or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Biohaven Pharmaceutical's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Biohaven Pharmaceutical Trading Alerts and Improvement Suggestions
| Biohaven Pharmaceutical generated a negative expected return over the last 90 days | |
| Biohaven Pharmaceutical has high historical volatility and very poor performance | |
| Biohaven Pharmaceutical Holding currently holds 32.78 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (582.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48. | |
| Biohaven Pharmaceutical has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies |
Biohaven Pharmaceutical Returns Distribution Density
The distribution of Biohaven Pharmaceutical's historical returns is an attempt to chart the uncertainty of Biohaven Pharmaceutical's future price movements. The chart of the probability distribution of Biohaven Pharmaceutical daily returns describes the distribution of returns around its average expected value. We use Biohaven Pharmaceutical Holding price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Biohaven Pharmaceutical returns is essential to provide solid investment advice for Biohaven Pharmaceutical.
| Mean Return | -0.5 | Value At Risk | -7.19 | Potential Upside | 4.39 | Standard Deviation | 3.87 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Biohaven Pharmaceutical historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Biohaven Pharmaceutical Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Biohaven Pharmaceutical or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Biohaven Pharmaceutical's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Biohaven stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.53 | |
β | Beta against Dow Jones | -0.18 | |
σ | Overall volatility | 3.87 | |
Ir | Information ratio | -0.1 |
Biohaven Pharmaceutical Volatility Alert
Biohaven Pharmaceutical Holding exhibits very low volatility with skewness of -0.37 and kurtosis of 2.32. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biohaven Pharmaceutical's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biohaven Pharmaceutical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Biohaven Pharmaceutical Fundamentals Vs Peers
Comparing Biohaven Pharmaceutical's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Biohaven Pharmaceutical's direct or indirect competition across all of the common fundamentals between Biohaven Pharmaceutical and the related equities. This way, we can detect undervalued stocks with similar characteristics as Biohaven Pharmaceutical or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Biohaven Pharmaceutical's fundamental indicators could also be used in its relative valuation, which is a method of valuing Biohaven Pharmaceutical by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Biohaven Pharmaceutical to competition |
| Fundamentals | Biohaven Pharmaceutical | Peer Average |
| Return On Equity | -1.99 | -0.31 |
| Return On Asset | -0.97 | -0.14 |
| Current Valuation | 2.55 B | 16.62 B |
| Shares Outstanding | 102.05 M | 571.82 M |
| Shares Owned By Insiders | 11.55 % | 10.09 % |
| Shares Owned By Institutions | 91.77 % | 39.21 % |
| Number Of Shares Shorted | 8.28 M | 4.71 M |
| Price To Earning | (4.25) X | 28.72 X |
| Price To Book | 7.09 X | 9.51 X |
| EBITDA | (885.11 M) | 3.9 B |
| Net Income | (846.42 M) | 570.98 M |
| Cash And Equivalents | 23.21 M | 2.7 B |
| Cash Per Share | 8.48 X | 5.01 X |
| Total Debt | 32.78 M | 5.32 B |
| Debt To Equity | 0.22 % | 48.70 % |
| Current Ratio | 0.71 X | 2.16 X |
| Book Value Per Share | 4.18 X | 1.93 K |
| Cash Flow From Operations | (582.45 M) | 971.22 M |
| Short Ratio | 10.98 X | 4.00 X |
| Earnings Per Share | (9.28) X | 3.12 X |
| Target Price | 63.47 | |
| Number Of Employees | 256 | 18.84 K |
| Beta | 3.91 | -0.15 |
| Market Capitalization | 2.88 B | 19.03 B |
| Total Asset | 615.11 M | 29.47 B |
| Retained Earnings | (1.35 B) | 9.33 B |
| Working Capital | 384.25 M | 1.48 B |
| Current Asset | 32.52 M | 9.34 B |
| Current Liabilities | 3.61 M | 7.9 B |
| Net Asset | 615.11 M |
Note: Acquisition by John Childs of 50000 shares of Biohaven Pharmaceutical at 18.4436 subject to Rule 16b-3 [view details]
Biohaven Pharmaceutical Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Biohaven . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Biohaven Pharmaceutical Buy or Sell Advice
When is the right time to buy or sell Biohaven Pharmaceutical Holding? Buying financial instruments such as Biohaven Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Biohaven Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Food Products Thematic Idea Now
Food Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Food Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Food Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Biohaven Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.